Point of Care Molecular Diagnostics Market by Product (Assays, Kits, Instruments, Software), Application (Respiratory Diseases, HAIs, Cancer, STDs, Hepatitis), Technology (RT-PCR, INAAT), End User (Clinics, Hospitals, ICUs) - Global Forecast to 2028
The global point-of-care molecular diagnostics market size is projected to reach USD 3.4 billion by 2028 from USD 2.0 billion in 2023, at a CAGR of 10.6% during the forecast period. Market growth is driven by factors such as the increasing prevalence of infectious diseases and cancer, rising focus on decentralized diagnostics and increasing R&D funding, increasing awareness on the early detection of infectious diseases, and the increasing use of POC diagnostic tests. On the other hand, stringent and time-consuming regulatory policies that significantly increase the product launch cycle may challenge market growth post their commercialization.
“The assays & kits accounted for the highest growth rate in the point-of-care molecular diagnostics market, by product & service, during the forecast period”
The point-of-care molecular diagnostics market is segmented into assays & kits, instruments & analyzers and software and services. The assays & kits segment accounted for the highest growth rate in the point-of-care molecular diagnostics market in 2022. The requirement assays & kits in large numbers compared to instruments is the main factor contributing to this segment's high growth rate. This segment's market growth can also be attributed to repeat purchases of assays & kits compared to instruments.
“Hospitals & ICUs segment accounted for the highest CAGR”
The point-of-care molecular diagnostics market is divided into various end-user segments, including physicians' offices, hospitals & ICUs, research institutes, and other end users. In 2022, the hospitals & ICUs segment experienced the most significant growth rate. One of the primary advantages of utilizing point-of-care molecular tests in hospitals or clinical settings, as opposed to traditional point-of-care tests, is their ability to provide faster turnaround times and increased accuracy. The hospitals & ICUs segment's substantial market share can be attributed to the growing number of hospitals and the high demand for diagnostic products within these healthcare facilities.
“Asia Pacific: The fastest-growing region point-of-care molecular diagnostics market”
The global market for point-of-care molecular diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these regions, the Asia Pacific region is anticipated to exhibit the highest compound annual growth rate (CAGR) throughout the forecast period. The remarkable growth in the Asia Pacific market can be attributed to several factors. These include the proactive efforts by governments to raise awareness about early disease detection and promote regular health check-ups, the increasing healthcare expenditure in the region, the rising number of hospitals and clinical diagnostic laboratories in countries like India and China, and the strengthening research capabilities in diagnostic procedures across India, China, and Japan.
The primary interviews conducted for this report can be categorized as follows:
Research Coverage:
This research report categorizes the point of care molecular diagnostics market by product & service, technology, application, end user and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the point-of-care molecular diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the point of care molecular diagnostics market. Competitive analysis of upcoming startups in the point of care molecular diagnostics market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall point-of-care molecular diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
“The assays & kits accounted for the highest growth rate in the point-of-care molecular diagnostics market, by product & service, during the forecast period”
The point-of-care molecular diagnostics market is segmented into assays & kits, instruments & analyzers and software and services. The assays & kits segment accounted for the highest growth rate in the point-of-care molecular diagnostics market in 2022. The requirement assays & kits in large numbers compared to instruments is the main factor contributing to this segment's high growth rate. This segment's market growth can also be attributed to repeat purchases of assays & kits compared to instruments.
“Hospitals & ICUs segment accounted for the highest CAGR”
The point-of-care molecular diagnostics market is divided into various end-user segments, including physicians' offices, hospitals & ICUs, research institutes, and other end users. In 2022, the hospitals & ICUs segment experienced the most significant growth rate. One of the primary advantages of utilizing point-of-care molecular tests in hospitals or clinical settings, as opposed to traditional point-of-care tests, is their ability to provide faster turnaround times and increased accuracy. The hospitals & ICUs segment's substantial market share can be attributed to the growing number of hospitals and the high demand for diagnostic products within these healthcare facilities.
“Asia Pacific: The fastest-growing region point-of-care molecular diagnostics market”
The global market for point-of-care molecular diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these regions, the Asia Pacific region is anticipated to exhibit the highest compound annual growth rate (CAGR) throughout the forecast period. The remarkable growth in the Asia Pacific market can be attributed to several factors. These include the proactive efforts by governments to raise awareness about early disease detection and promote regular health check-ups, the increasing healthcare expenditure in the region, the rising number of hospitals and clinical diagnostic laboratories in countries like India and China, and the strengthening research capabilities in diagnostic procedures across India, China, and Japan.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18% and Latin America 6% and Middle East & Africa 4%
Research Coverage:
This research report categorizes the point of care molecular diagnostics market by product & service, technology, application, end user and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the point-of-care molecular diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the point of care molecular diagnostics market. Competitive analysis of upcoming startups in the point of care molecular diagnostics market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall point-of-care molecular diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the point of care molecular diagnostics market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the point of care molecular diagnostics market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the point of care molecular diagnostics market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the point of care molecular diagnostics market.
- Competitive Assessment: In-depth assessment of market ranking, growth strategies and service offerings of leading players like Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioM?rieux SA (France), Danaher Corporation (US), and QIAGEN N.V. (Netherlands), among others in the point of care molecular diagnostics market strategies.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKETS COVERED
1.3.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY
1.5 STUDY LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 LIMITATIONS
2.8 RISK ASSESSMENT
2.8.1 RISK ASSESSMENT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
2.9 RECESSION IMPACT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY
FIGURE 8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
FIGURE 9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 11 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 12 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW
FIGURE 13 RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD
4.2 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2023 VS. 2028
FIGURE 14 ASSAYS & KITS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028
4.3 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2023 VS. 2028
FIGURE 15 RT-PCR SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION, 2023 VS. 2028
FIGURE 16 RESPIRATORY DISEASES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.5 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER, 2023 VS. 2028
FIGURE 17 PHYSICIANS’ OFFICES SEGMENT TO CONTINUE TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
4.6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of infectious diseases and cancer
5.2.1.2 Rising focus on decentralized diagnostics and increasing R&D funding
5.2.1.3 Growing awareness of the early detection of infectious diseases
5.2.1.4 Increasing use of POC diagnostic tests
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
5.2.2.2 High capital investments and low cost-benefit ratio
5.2.3 OPPORTUNITIES
5.2.3.1 Growing R&D activities in point-of-care molecular diagnostics testing
5.2.3.2 Growth opportunities in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Stringent and time-consuming regulatory policies that significantly increase product launch cycle
5.2.4.2 Introduction of alternative technologies
5.3 PRICING ANALYSIS
TABLE 1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT
5.4 PATENT ANALYSIS
FIGURE 20 PATENT ANALYSIS FOR POINT-OF-CARE MOLECULAR DIAGNOSTICS (JANUARY 2013–DECEMBER 2022)
5.4.1 LIST OF KEY PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
5.7.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 2 PORTER’S FIVE FORCES ANALYSIS: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 PESTLE ANALYSIS
5.10 REGULATORY ANALYSIS
TABLE 3 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 4 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.1.1 North America
5.10.1.1.1 US
5.10.1.1.2 Canada
5.10.1.2 Europe
5.10.1.3 Asia Pacific
5.10.1.3.1 China
5.10.1.3.2 Japan
5.10.1.3.3 India
5.10.1.4 Latin America
5.10.1.4.1 Brazil
5.10.1.4.2 Mexico
5.10.1.5 Middle East
5.10.1.6 Africa
5.11 TRADE ANALYSIS
TABLE 8 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 9 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
5.12 TECHNOLOGY ANALYSIS
5.13 KEY CONFERENCES AND EVENTS, 2023–2024
TABLE 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 24 REVENUE SHIFT IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS
TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS
5.15.2 BUYING CRITERIA
FIGURE 26 KEY BUYING CRITERIA FOR POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS
TABLE 12 KEY BUYING CRITERIA FOR POINT-OF-CARE MOLECULAR DIAGNOSTIC PRODUCTS
6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 13 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
6.2 ASSAYS & KITS
6.2.1 RECURRENT PURCHASES OF ASSAYS & KITS TO DRIVE GROWTH
TABLE 14 KEY ASSAYS & KITS AVAILABLE IN MARKET
TABLE 15 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS & ANALYZERS
6.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE GROWTH IN MARKET
TABLE 16 KEY INSTRUMENTS & ANALYZERS AVAILABLE IN MARKET
TABLE 17 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2021–2028 (USD MILLION)
6.4 SOFTWARE & SERVICES
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE DEMAND
TABLE 18 KEY SOFTWARE & SERVICES AVAILABLE IN MARKET
TABLE 19 POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION)
7 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 20 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 RT-PCR
7.2.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
TABLE 21 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2021–2028 (USD MILLION)
7.3 INAAT
7.3.1 COST BENEFITS OF INAAT TO BOOST DEMAND
TABLE 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021–2028 (USD MILLION)
7.4 OTHER TECHNOLOGIES
TABLE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 24 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
8.2 RESPIRATORY DISEASES
8.2.1 RISING DEMAND FOR EARLY DIAGNOSIS AND DETECTION OF RESPIRATORY DISEASES TO DRIVE GROWTH
TABLE 25 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2021–2028 (USD MILLION)
8.3 SEXUALLY TRANSMITTED DISEASES
8.3.1 TECHNOLOGICAL ADVANCEMENTS FOR DETECTION OF STDS TO FAVOR MARKET GROWTH
TABLE 26 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2021–2028 (USD MILLION)
8.4 HOSPITAL-ACQUIRED INFECTIONS
8.4.1 RISING BURDEN OF MRSA TO SUPPORT GROWTH
TABLE 27 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021–2028 (USD MILLION)
8.5 CANCER
8.5.1 RISING PREVALENCE OF CANCER AND GROWING FUNDING FOR CANCER RESEARCH TO DRIVE MARKET
TABLE 28 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION)
8.6 HEPATITIS
8.6.1 INCREASING CASES OF HEPATITIS AMONG HIGH-RISK SUBGROUP POPULATIONS TO BOOST GROWTH
TABLE 29 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2021–2028 (USD MILLION)
8.7 GASTROINTESTINAL DISORDERS
8.7.1 GROWING INCIDENCE OF GASTROINTESTINAL DISORDERS TO PROPEL MARKET
TABLE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
8.8 OTHER APPLICATIONS
TABLE 31 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
8.9 COVID-19
8.9.1 DECLINING CASES OF COVID-19 TO HINDER MARKET GROWTH
TABLE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021–2028 (USD MILLION)
9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 33 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 PHYSICIANS’ OFFICES
9.2.1 FASTER RESULTS ASSOCIATED WITH POINT-OF-CARE MOLECULAR ASSAYS TO DRIVE GROWTH
TABLE 34 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES, BY REGION, 2021–2028 (USD MILLION)
9.3 HOSPITALS & ICUS
TABLE 35 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY REGION, 2021–2028 (USD MILLION)
TABLE 36 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2021–2028 (USD MILLION)
9.3.1 SEPSIS
9.3.1.1 Growing need for quick diagnosis and treatment to favor market growth
9.3.2 GASTROENTERITIS
9.3.2.1 Growing incidence of gastroenteritis cases in emergency departments to propel growth
9.3.3 MENINGOENCEPHALITIS
9.3.3.1 Severity of disease and need for early detection to drive demand
9.3.4 OTHER DISEASES
9.4 RESEARCH INSTITUTES
9.4.1 INCREASING USE OF POC MOLECULAR DIAGNOSTIC TESTS IN GENOMICS RESEARCH TO CONTRIBUTE TO MARKET GROWTH
TABLE 37 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
9.5 OTHER END USERS
TABLE 38 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION
10.1 INTRODUCTION
TABLE 39 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
10.2.1 RECESSION IMPACT: NORTH AMERICA
FIGURE 27 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 40 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 41 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 42 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 43 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 44 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.2 US
10.2.2.1 Growing prevalence of infectious diseases to drive market
TABLE 45 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 46 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 47 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 48 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Rising government initiatives to propel market growth in coming years
TABLE 49 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 50 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 51 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 52 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
10.3.1 RECESSION IMPACT: EUROPE
TABLE 53 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 55 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 56 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 57 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Increasing healthcare expenditure to drive market growth in Germany
TABLE 58 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 59 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 60 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 61 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 UK
10.3.3.1 Increasing prevalence of infectious diseases to fuel growth
TABLE 62 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 63 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 64 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 65 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Rising R&D expenditure in France to boost market
TABLE 66 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 67 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 68 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 69 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Adoption of advanced diagnostic technologies to favor growth
TABLE 70 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 71 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 72 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 73 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Growing demand for genetic testing in Spain to create major growth opportunities for market players
TABLE 74 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 75 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 76 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 77 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 78 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 79 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 80 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 81 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
10.4.1 RECESSION IMPACT: ASIA PACIFIC
FIGURE 28 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 82 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 83 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 84 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 85 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 86 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Growing public access to modern healthcare to drive market growth
TABLE 87 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 88 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 89 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 90 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 JAPAN
10.4.3.1 Universal healthcare reimbursement policy to drive market growth in Japan
TABLE 91 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 92 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 93 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 94 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Increasing private & public investments in healthcare system to support market growth
TABLE 95 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 96 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 97 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 98 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC (ROAPAC)
TABLE 99 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 100 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 101 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 102 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 LOW PER CAPITA HEALTH SPENDING TO RESTRAIN MARKET GROWTH
10.5.2 RECESSION IMPACT: LATIN AMERICA
TABLE 103 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 104 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 105 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 106 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 LACK OF SKILLED RESOURCES TO RESTRICT MARKET GROWTH
10.6.2 RECESSION IMPACT: MIDDLE EAST & AFRICA
TABLE 107 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 108 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 109 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 110 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 STRATEGIES OF KEY PLAYERS
11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
TABLE 111 OVERVIEW OF STRATEGIES DEPLOYED BY KEY POINT-OF-CARE MOLECULAR DIAGNOSTICS MANUFACTURING COMPANIES
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET (2018–2022)
11.4 MARKET SHARE ANALYSIS
FIGURE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022)
TABLE 112 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT
11.5.1 LIST OF EVALUATED VENDORS
11.5.2 STARS
11.5.3 EMERGING LEADERS
11.5.4 PERVASIVE PLAYERS
11.5.5 PARTICIPANTS
FIGURE 31 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2022
11.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2022)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2022
11.7 COMPETITIVE BENCHMARKING
11.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
FIGURE 33 PRODUCT & SERVICE AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
TABLE 113 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY REGIONAL FOOTPRINT
TABLE 114 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY PRODUCT & SERVICE FOOTPRINT
TABLE 115 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
11.8 COMPETITIVE SCENARIO
11.8.1 PRODUCT LAUNCHES & APPROVALS
TABLE 116 KEY PRODUCT LAUNCHES & APPROVALS
11.8.2 DEALS
TABLE 117 KEY DEALS
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 ABBOTT LABORATORIES
TABLE 118 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 34 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
12.1.2 F. HOFFMANN-LA ROCHE LTD.
TABLE 119 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
12.1.3 BIOM?RIEUX SA
TABLE 120 BIOM?RIEUX SA: BUSINESS OVERVIEW
FIGURE 36 BIOM?RIEUX SA: COMPANY SNAPSHOT (2022)
12.1.4 DANAHER CORPORATION
TABLE 121 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
12.1.5 QIAGEN N.V.
TABLE 122 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 38 QIAGEN N.V.: COMPANY SNAPSHOT (2022)
12.1.6 QUIDELORTHO CORPORATION
TABLE 123 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW
FIGURE 39 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
12.1.7 CO-DIAGNOSTICS, INC.
TABLE 124 CO-DIAGNOSTICS INC.: BUSINESS OVERVIEW
FIGURE 40 CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)
12.1.8 BIOCARTIS NV
TABLE 125 BIOCARTIS NV: BUSINESS OVERVIEW
FIGURE 41 BIOCARTIS NV: COMPANY SNAPSHOT (2022)
12.1.9 MERIDIAN BIOSCIENCE, INC.
TABLE 126 MERIDIAN BIOSCIENCE, INC.: BUSINESS OVERVIEW
FIGURE 42 MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2022)
12.1.10 THERMO FISHER SCIENTIFIC INC.
TABLE 127 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 LUCIRA HEALTH, INC.
12.2.2 CUE HEALTH
12.2.3 OPGEN, INC.
12.2.4 BINX HEALTH, INC.
12.2.5 MOLBIO DIAGNOSTICS PVT. LTD.
12.2.6 GENOMADIX
12.2.7 VISBY MEDICAL, INC.
12.2.8 QUIKPATH PTE. LTD.
12.2.9 MD-BIO
12.2.10 QUANTUMDX GROUP LTD.
12.2.11 AIDIAN OY
12.2.12 GENESTAT MOLECULAR DIAGNOSTICS, LLC.
12.2.13 LABSYSTEMS DIAGNOSTICS OY
12.2.14 AKONNI BIOSYSTEMS
12.2.15 CURETIS N.V.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKETS COVERED
1.3.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY
1.5 STUDY LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 LIMITATIONS
2.8 RISK ASSESSMENT
2.8.1 RISK ASSESSMENT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
2.9 RECESSION IMPACT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY
FIGURE 8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
FIGURE 9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 11 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 12 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW
FIGURE 13 RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD
4.2 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2023 VS. 2028
FIGURE 14 ASSAYS & KITS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028
4.3 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2023 VS. 2028
FIGURE 15 RT-PCR SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION, 2023 VS. 2028
FIGURE 16 RESPIRATORY DISEASES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.5 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER, 2023 VS. 2028
FIGURE 17 PHYSICIANS’ OFFICES SEGMENT TO CONTINUE TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
4.6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of infectious diseases and cancer
5.2.1.2 Rising focus on decentralized diagnostics and increasing R&D funding
5.2.1.3 Growing awareness of the early detection of infectious diseases
5.2.1.4 Increasing use of POC diagnostic tests
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
5.2.2.2 High capital investments and low cost-benefit ratio
5.2.3 OPPORTUNITIES
5.2.3.1 Growing R&D activities in point-of-care molecular diagnostics testing
5.2.3.2 Growth opportunities in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Stringent and time-consuming regulatory policies that significantly increase product launch cycle
5.2.4.2 Introduction of alternative technologies
5.3 PRICING ANALYSIS
TABLE 1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT
5.4 PATENT ANALYSIS
FIGURE 20 PATENT ANALYSIS FOR POINT-OF-CARE MOLECULAR DIAGNOSTICS (JANUARY 2013–DECEMBER 2022)
5.4.1 LIST OF KEY PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
5.7.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 2 PORTER’S FIVE FORCES ANALYSIS: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 PESTLE ANALYSIS
5.10 REGULATORY ANALYSIS
TABLE 3 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 4 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.1.1 North America
5.10.1.1.1 US
5.10.1.1.2 Canada
5.10.1.2 Europe
5.10.1.3 Asia Pacific
5.10.1.3.1 China
5.10.1.3.2 Japan
5.10.1.3.3 India
5.10.1.4 Latin America
5.10.1.4.1 Brazil
5.10.1.4.2 Mexico
5.10.1.5 Middle East
5.10.1.6 Africa
5.11 TRADE ANALYSIS
TABLE 8 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 9 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
5.12 TECHNOLOGY ANALYSIS
5.13 KEY CONFERENCES AND EVENTS, 2023–2024
TABLE 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 24 REVENUE SHIFT IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS
TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS
5.15.2 BUYING CRITERIA
FIGURE 26 KEY BUYING CRITERIA FOR POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS
TABLE 12 KEY BUYING CRITERIA FOR POINT-OF-CARE MOLECULAR DIAGNOSTIC PRODUCTS
6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 13 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
6.2 ASSAYS & KITS
6.2.1 RECURRENT PURCHASES OF ASSAYS & KITS TO DRIVE GROWTH
TABLE 14 KEY ASSAYS & KITS AVAILABLE IN MARKET
TABLE 15 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS & ANALYZERS
6.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE GROWTH IN MARKET
TABLE 16 KEY INSTRUMENTS & ANALYZERS AVAILABLE IN MARKET
TABLE 17 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2021–2028 (USD MILLION)
6.4 SOFTWARE & SERVICES
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE DEMAND
TABLE 18 KEY SOFTWARE & SERVICES AVAILABLE IN MARKET
TABLE 19 POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION)
7 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 20 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 RT-PCR
7.2.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
TABLE 21 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2021–2028 (USD MILLION)
7.3 INAAT
7.3.1 COST BENEFITS OF INAAT TO BOOST DEMAND
TABLE 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021–2028 (USD MILLION)
7.4 OTHER TECHNOLOGIES
TABLE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 24 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
8.2 RESPIRATORY DISEASES
8.2.1 RISING DEMAND FOR EARLY DIAGNOSIS AND DETECTION OF RESPIRATORY DISEASES TO DRIVE GROWTH
TABLE 25 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2021–2028 (USD MILLION)
8.3 SEXUALLY TRANSMITTED DISEASES
8.3.1 TECHNOLOGICAL ADVANCEMENTS FOR DETECTION OF STDS TO FAVOR MARKET GROWTH
TABLE 26 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2021–2028 (USD MILLION)
8.4 HOSPITAL-ACQUIRED INFECTIONS
8.4.1 RISING BURDEN OF MRSA TO SUPPORT GROWTH
TABLE 27 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021–2028 (USD MILLION)
8.5 CANCER
8.5.1 RISING PREVALENCE OF CANCER AND GROWING FUNDING FOR CANCER RESEARCH TO DRIVE MARKET
TABLE 28 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION)
8.6 HEPATITIS
8.6.1 INCREASING CASES OF HEPATITIS AMONG HIGH-RISK SUBGROUP POPULATIONS TO BOOST GROWTH
TABLE 29 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2021–2028 (USD MILLION)
8.7 GASTROINTESTINAL DISORDERS
8.7.1 GROWING INCIDENCE OF GASTROINTESTINAL DISORDERS TO PROPEL MARKET
TABLE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
8.8 OTHER APPLICATIONS
TABLE 31 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
8.9 COVID-19
8.9.1 DECLINING CASES OF COVID-19 TO HINDER MARKET GROWTH
TABLE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021–2028 (USD MILLION)
9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 33 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 PHYSICIANS’ OFFICES
9.2.1 FASTER RESULTS ASSOCIATED WITH POINT-OF-CARE MOLECULAR ASSAYS TO DRIVE GROWTH
TABLE 34 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES, BY REGION, 2021–2028 (USD MILLION)
9.3 HOSPITALS & ICUS
TABLE 35 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY REGION, 2021–2028 (USD MILLION)
TABLE 36 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2021–2028 (USD MILLION)
9.3.1 SEPSIS
9.3.1.1 Growing need for quick diagnosis and treatment to favor market growth
9.3.2 GASTROENTERITIS
9.3.2.1 Growing incidence of gastroenteritis cases in emergency departments to propel growth
9.3.3 MENINGOENCEPHALITIS
9.3.3.1 Severity of disease and need for early detection to drive demand
9.3.4 OTHER DISEASES
9.4 RESEARCH INSTITUTES
9.4.1 INCREASING USE OF POC MOLECULAR DIAGNOSTIC TESTS IN GENOMICS RESEARCH TO CONTRIBUTE TO MARKET GROWTH
TABLE 37 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
9.5 OTHER END USERS
TABLE 38 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION
10.1 INTRODUCTION
TABLE 39 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
10.2.1 RECESSION IMPACT: NORTH AMERICA
FIGURE 27 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 40 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 41 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 42 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 43 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 44 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.2 US
10.2.2.1 Growing prevalence of infectious diseases to drive market
TABLE 45 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 46 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 47 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 48 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Rising government initiatives to propel market growth in coming years
TABLE 49 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 50 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 51 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 52 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
10.3.1 RECESSION IMPACT: EUROPE
TABLE 53 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 55 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 56 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 57 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Increasing healthcare expenditure to drive market growth in Germany
TABLE 58 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 59 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 60 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 61 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 UK
10.3.3.1 Increasing prevalence of infectious diseases to fuel growth
TABLE 62 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 63 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 64 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 65 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Rising R&D expenditure in France to boost market
TABLE 66 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 67 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 68 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 69 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Adoption of advanced diagnostic technologies to favor growth
TABLE 70 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 71 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 72 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 73 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Growing demand for genetic testing in Spain to create major growth opportunities for market players
TABLE 74 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 75 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 76 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 77 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 78 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 79 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 80 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 81 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
10.4.1 RECESSION IMPACT: ASIA PACIFIC
FIGURE 28 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 82 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 83 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 84 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 85 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 86 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Growing public access to modern healthcare to drive market growth
TABLE 87 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 88 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 89 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 90 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 JAPAN
10.4.3.1 Universal healthcare reimbursement policy to drive market growth in Japan
TABLE 91 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 92 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 93 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 94 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Increasing private & public investments in healthcare system to support market growth
TABLE 95 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 96 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 97 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 98 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC (ROAPAC)
TABLE 99 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 100 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 101 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 102 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 LOW PER CAPITA HEALTH SPENDING TO RESTRAIN MARKET GROWTH
10.5.2 RECESSION IMPACT: LATIN AMERICA
TABLE 103 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 104 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 105 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 106 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 LACK OF SKILLED RESOURCES TO RESTRICT MARKET GROWTH
10.6.2 RECESSION IMPACT: MIDDLE EAST & AFRICA
TABLE 107 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 108 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 109 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 110 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 STRATEGIES OF KEY PLAYERS
11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
TABLE 111 OVERVIEW OF STRATEGIES DEPLOYED BY KEY POINT-OF-CARE MOLECULAR DIAGNOSTICS MANUFACTURING COMPANIES
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET (2018–2022)
11.4 MARKET SHARE ANALYSIS
FIGURE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022)
TABLE 112 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT
11.5.1 LIST OF EVALUATED VENDORS
11.5.2 STARS
11.5.3 EMERGING LEADERS
11.5.4 PERVASIVE PLAYERS
11.5.5 PARTICIPANTS
FIGURE 31 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2022
11.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2022)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2022
11.7 COMPETITIVE BENCHMARKING
11.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
FIGURE 33 PRODUCT & SERVICE AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
TABLE 113 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY REGIONAL FOOTPRINT
TABLE 114 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY PRODUCT & SERVICE FOOTPRINT
TABLE 115 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
11.8 COMPETITIVE SCENARIO
11.8.1 PRODUCT LAUNCHES & APPROVALS
TABLE 116 KEY PRODUCT LAUNCHES & APPROVALS
11.8.2 DEALS
TABLE 117 KEY DEALS
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 ABBOTT LABORATORIES
TABLE 118 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 34 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
12.1.2 F. HOFFMANN-LA ROCHE LTD.
TABLE 119 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
12.1.3 BIOM?RIEUX SA
TABLE 120 BIOM?RIEUX SA: BUSINESS OVERVIEW
FIGURE 36 BIOM?RIEUX SA: COMPANY SNAPSHOT (2022)
12.1.4 DANAHER CORPORATION
TABLE 121 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
12.1.5 QIAGEN N.V.
TABLE 122 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 38 QIAGEN N.V.: COMPANY SNAPSHOT (2022)
12.1.6 QUIDELORTHO CORPORATION
TABLE 123 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW
FIGURE 39 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
12.1.7 CO-DIAGNOSTICS, INC.
TABLE 124 CO-DIAGNOSTICS INC.: BUSINESS OVERVIEW
FIGURE 40 CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)
12.1.8 BIOCARTIS NV
TABLE 125 BIOCARTIS NV: BUSINESS OVERVIEW
FIGURE 41 BIOCARTIS NV: COMPANY SNAPSHOT (2022)
12.1.9 MERIDIAN BIOSCIENCE, INC.
TABLE 126 MERIDIAN BIOSCIENCE, INC.: BUSINESS OVERVIEW
FIGURE 42 MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2022)
12.1.10 THERMO FISHER SCIENTIFIC INC.
TABLE 127 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 LUCIRA HEALTH, INC.
12.2.2 CUE HEALTH
12.2.3 OPGEN, INC.
12.2.4 BINX HEALTH, INC.
12.2.5 MOLBIO DIAGNOSTICS PVT. LTD.
12.2.6 GENOMADIX
12.2.7 VISBY MEDICAL, INC.
12.2.8 QUIKPATH PTE. LTD.
12.2.9 MD-BIO
12.2.10 QUANTUMDX GROUP LTD.
12.2.11 AIDIAN OY
12.2.12 GENESTAT MOLECULAR DIAGNOSTICS, LLC.
12.2.13 LABSYSTEMS DIAGNOSTICS OY
12.2.14 AKONNI BIOSYSTEMS
12.2.15 CURETIS N.V.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
